The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells

Tobias Furlan‡, Sana Khalid†‡, Anh-Vu Nguyen, Julia Günther and Jakob Troppmair

Daniel Swarovski Research Laboratory, Department of Visceral-, Transplant- and Thoracic Surgery, Medical University of Innsbruck (MUI), Austria

Keywords
BRAFV600E; intracellular signaling; mitochondria; p66Shc; ROS; vemurafenib resistance

Correspondence
J. Troppmair, Daniel Swarovski Research Laboratory (DSL), Department of Visceral-, Transplant- and Thoracic Surgery (VTT), Medical University of Innsbruck (MUI), Innrain 66, 6020 Innsbruck, Austria
Fax: +43 51250424625
Tel: +43 51250427819
E-mail: jakob.troppmair@i-med.ac.at

† Present address
Oral Biology, Department of Dental Medicine, University of Pittsburgh, Salk Pavilion Room 422A, 335 Sutherland Drive, Pittsburgh, PA 15213-2523, USA

‡ These authors contributed equally to this work

(Received 29 November 2017, revised 26 February 2018, accepted 14 March 2018, available online 5 May 2018)

doi:10.1002/1878-0261.12199

Metabolic reprogramming, as exemplified by the shift from oxidative phosphorylation to glycolysis, is a common feature of transformed cells. In many tumors, altered metabolism is also reflected in increased reactive oxygen species (ROS) levels, which contribute to proliferation and survival signaling. However, despite high ROS levels, cancer cells can be efficiently killed by further increasing ROS production. We have shown previously that both wild-type and oncogenic CRAF and BRAF prevent excessive mitochondrial ROS production. Subsequently, it has been demonstrated that raising ROS levels in BRAFV600E-transformed melanoma cells by inhibiting BRAF or MEK rendered them susceptible to cell death induction. To understand how oncogenic BRAF affects mitochondrial ROS production in melanoma, we studied the mitochondrial ROS-producing oxidoreductase p66Shc, which is frequently overexpressed in tumors. Using NIH 3T3 BRAFV600E fibroblasts and the melanoma cell lines A375 and M238 carrying the same BRAF mutation, we show that under treatment with the ROS-inducing agent phenethyl isothiocyanate (PEITC), oncogenic BRAF renders cells refractory to p66ShcS36 phosphorylation, which is essential for p66Shc activation and mitochondrial ROS production. Consistent with this, the activation of JNK1/2, which phosphorylate S36, was blunted, while other mitogen-activated protein kinases were not affected. Inhibition of JNK1/2 efficiently prevented ROS production, while BRAF and MEK inhibitors increased ROS levels. Vemurafenib-resistant M238R melanoma cells were impaired in S36 phosphorylation and ROS production following PEITC treatment. Moreover, they failed to increase ROS levels after MEK/BRAF inhibition. Finally, shRNA-mediated knockdown of p66Shc led to increased growth of BRAFV600E-transformed NIH 3T3 cells in soft agar assay. Taken together, these data suggest that phosphorylation-activated p66Shc functions as a tumor suppressor in melanoma cells.

1. Introduction

One hallmark of the progression toward a malignant state in cancer is a metabolic rewiring, which allows tumor cells to cope with the increased need for molecular biosynthesis while maintaining sufficient energy production (Kroemer and Pouyssegur, 2008). A frequently observed feature is the switch to glycolysis even under aerobic conditions. A major driving force behind this are oncogenes and tumor suppressor genes,
which through transcription-dependent and transcription-independent mechanisms regulate the activity of key metabolic pathways (Rathmell et al., 2003; Ward and Thompson, 2012). Additionally, metabolic enzymes themselves may be prone to mutations (Gottlieb and Tomlinson, 2005; King et al., 2006). Despite the decline in oxidative phosphorylation, tumors frequently show increased reactive oxygen species (ROS) levels. Apart from mitochondria, NADPH-dependent oxidases (NOXs), for example, activated through RAS/RAC-dependent pathways downstream of oncogenic RAS and mutant receptor tyrosine kinases, contribute to this increase (Yang et al., 2016b). High levels of ROS favor tumor progression through their DNA-damaging activity enhancing mutation frequency, while at lower concentration their function as important intracellular signaling molecules predominates (Birben et al., 2012; Martindale and Holbrook, 2002; Son et al., 2013). Despite their need for increased ROS levels, tumor cells remain exquisitely sensitive to a further rise in ROS (Trachootham et al., 2006). Boosting ROS levels to kill tumor cells is part of the effect of cytostatic and radiation therapy (Galadari et al., 2017; Gorrini et al., 2013; Trachootham et al., 2009). However, lowering intracellular ROS levels may also harm tumors due to decreased proliferation and survival signaling (Kim et al., 2016; Liu et al., 2016).

Other groups, as well as our own, have shown in the past that mitochondrial ROS levels are subject to control by intracellular signaling pathways, which affect ROS production but also the detoxification of ROS by antioxidant systems (Acin-Perez et al., 2009; Ashraf et al., 2014; Bensaud and Vousden, 2007; Churchill and Mochly-Rosen, 2007; Koziel et al., 2013; Kuznetsov et al., 2008; Liu et al., 2008; Piccoli et al., 2006; Ramanathan and Schreiber, 2009; Sucher et al., 2009; Zhu and Prives, 2009). One source of mitochondrial ROS, which has been extensively studied in the past, is the oxidoreductase p66Shc, which has been linked to redox stress in many pathological settings and diseases (Galmov, 2010). In contrast to other ROS-generating systems, p66Shc ablation did not interfere with normal cell survival (Giorgio et al., 2005), which was not the case for NOX-dependent ROS production or the inhibition of the electron transport chain (ETC) (Brand et al., 2016; Matsushima et al., 2013). Enforced expression of p66Shc was sufficient to inhibit the growth of the breast cancer cell line MCF-7 in a process involving ROS (Yang et al., 2016a). Moreover, p66Shc-dependent induction of ROS by phenethyl isothiocyanate (PEITC) was required for the killing of prostate cancer cells (Xiao and Singh, 2010). In contrast to most other solid tumors, melanomas are characterized by moderate ROS levels (Lebiedzinska-Arciszewska et al., 2015). Melanomas frequently carry an activating mutation in BRAF, most commonly an exchange of valine (V) to glutamic acid (E) at amino acid position 600 (Wellbrock et al., 2004; Zebisch et al., 2007). In the past, we have shown that signaling through wild-type (wt) and oncogenic RAF kinases (BRAF and CRAF) prevents excessive mitochondrial ROS production (Kuznetsov et al., 2008), without altering the antioxidant capacity of the cells (Koziel et al., 2013). Additional published work confirmed the requirement of ROS in the killing of melanoma cells following inhibition of MEK or mutant BRAF (Bauer et al., 2017; Verhaegen et al., 2006).

We have recently dissected in detail the regulation of p66Shc activation and have provided evidence for the requirement of PKCβ and the MAPKs JNK1 and JNK2 for the phosphorylation activation of p66Shc (Haller et al., 2016; Khalid et al., 2016). Understanding the crosstalk between oncogene signaling, ROS production by p66Shc, and transformation may identify novel targets for treating melanoma and possibly help to overcome the development of resistance to mutant BRAF-specific kinase inhibitors (Luke et al., 2017).

2. Materials and methods

2.1. Cell culture, kinase inhibitors, and plasmid transfection

NIH 3T3 (NIH 3T3 wt), NIH 3T3 BRAFV600E (NIH 3T3 V600E), A375, M238, and M238R cells were cultured in T75 flasks containing 20 mL of Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Basel, Switzerland) with 10% FBS (PAA Laboratories, Coelbe, Germany), 1 x penicillin–streptomycin (5000 U·mL⁻¹; Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C in a humidified 5% CO₂/95% air mixture. A375, M238, and M238R are melanoma cell lines which carry the BRAFV600E mutation. M238R cells have been rendered nonresponsive to PLX4032 treatment (Nazarian et al., 2010). For microscopic analyses of cells, an 8-well Nunc Lab-Tek chamber slide system was used (Thermo Fisher Scientific, Waltham, MA, USA). For knockdown of p66Shc, the plasmids pRetro-SUPER p66 shRNA (Marco Giorgio, Department of Experimental Oncology, Institute of Oncology, Milan, Italy) and pRetro-SUPER scrambled (DSL) were used. Cells were
seeded in six-well plates, and up to 1 µg of plasmid DNA was transfected using Lipofectamine (Thermo Fisher Scientific) according to the manufacturer's instructions.

2.2. Protein analysis and immunoblotting

Cells were washed twice with PBS, and the pellet was resuspended in 200 µL of ice-cold NP-40 lysis buffer (Haller et al., 2016; Khalid et al., 2016) with 10 µL·mL⁻¹ of Protease Inhibitor Cocktail Set I – Calbiochem (Merck Millipore, Billerica, MA, USA). Lysates were spun down at 13 000 g for 20 min at 4 °C. The supernatant was transferred to a fresh Eppendorf tube, and the protein concentration was measured (Bio-Rad DC protein assay kit; Bio-Rad, Hercules, CA, USA). Samples were adjusted to equal protein concentrations, mixed with 6× Laemmli, and heated at 95 °C for 5 min. Up to 60 µg of total protein was separated on 7.5, 10, or 12.5% gels by SDS/PAGE and subsequently blotted onto nitrocellulose membranes. Immunoblotting was carried out as described previously (Haller et al., 2016; Khalid et al., 2016). The following antibodies were used: Shc1 (610082; BD Biosciences, San Jose, CA, USA), p66S36 (ab54518; Abcam, Cambridge, UK), α-tubulin (T5168; Sigma, St. Louis, MO, USA), GAPDH (Ambion AM4300; Thermo Fisher Scientific), ERK1/2 (sc-94; Santa Cruz Biotechnology, Dallas, TX, USA), pERK1/2 (sc-16982-R; Santa Cruz Biotechnology), JNK1/2 (sc-571; Santa Cruz Biotechnology), pJNK1/2 (9251S; Cell Signaling Technology, Leiden, The Netherlands), p38 (9212; Cell Signaling Technology), and pp38 (9211; Cell Signaling Technology). The vinculin antibody was obtained from Santa Cruz (sc-25336). Detection was done with a fluorescence-labelled secondary antibodies (Molecular Probes, Eugene, OR, USA). Detection and quantifications of bands were performed by using Odyssey Infrared Imaging System (LiCor Biosciences, Lincoln, NE, USA).

2.3. Cell death analysis

Cells were seeded in six-well plates and treated with PEITC (Sigma-Aldrich, St. Louis, MO, USA) as indicated. Cells were washed with 2 mL of PBS (PAA Laboratories), detached with 500 µL of trypsin/EDTA (PAA Laboratories), and transferred to 5-mL Falcon tubes (Corning, Wiesbaden, Germany) together with the supernatant. After centrifugation at 200 g for 5 min at room temperature, the pellet was resuspended in 30 µL of staining solution containing annexin V (FITC) (Enzo Life Sciences, Farmingdale, NY, USA) and propidium iodide (Carl Roth GmbH Co KG, Karlsruhe, Germany) as described previously (Khalid et al., 2016). After incubation, the cells were mixed with 400 µL of binding buffer and centrifuged at 200 g for 5 min. The supernatant was decanted, and the cells were resuspended in growth medium on ice. The samples were analyzed immediately.

2.4. Reactive oxygen species (ROS) measurements

To measure ROS, 60 000 cells were seeded in 8-well Nunc Lab-Tek chambers (Thermo Fisher Scientific). The next day, cells were first stressed as indicated and then stained using MitoTracker Red CM-H2XRos (Life Technologies, Carlsbad, CA, USA) at a concentration of 0.2 µM diluted in serum-free DMEM, at 37 °C and 5% CO₂ for 30 min. Before microscopy, cells were resupplied with DMEM/FBS. Digital images were taken using an Olympus IX70 inverted microscope (numerical aperture 0.8) and an Olympus U-RFL-T mercury-vapor lamp (Olympus, Vienna, Austria). Images were acquired using a Kappa ACC1 camera and Kappa IMAGEBASE software (Kappa Optronics, Gleichen, Germany). Gray values were quantified using SCION IMAGE software for Windows (Scion Corporation, Frederick, MD, USA). For every experimental condition, gray values for 80–100 cells were averaged. Alternatively, 500 000 cells were seeded in six-well plates and treated with different inhibitors for 1 h. To detach cells, they were washed with 2 mL of PBS and treated with 300 µL of trypsin/EDTA for 3 min in the cell culture incubator. Afterward, cells were resuspended in 5 mL of PBS, transferred to FACS tubes, and centrifuged at 200 g for 5 min. The pellet was resupplied with 1 mL of complete growth medium and inhibitors in addition to different concentrations of PEITC. After 45 min, 4 mL of PBS was added and cells were centrifuged at 200 g for 5 min. To stain the cells for ROS, the supernatant was decanted and 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) (Life Technologies, USA) was added. DCFDA was first dissolved in 100% ethanol and subsequently diluted in serum-free medium to a concentration of 10 µM. The cells were incubated for 10 min in the tissue culture incubator in the dark. Before FACS analysis, cells were resupplied with 4 mL of complete growth medium and centrifuged at 200 g for 5 min, and the pellet was resuspended in 400 µL of complete growth medium. FACS analyses were performed on a BD FACS Calibur (BD Biosciences).

2.5. Soft agar assay

A 2% SeaPlaque agarose (Biozym Scientific GmbH, Hessisch Oldendorf, Germany) solution dissolved in
PBS was autoclaved and diluted to 0.5% with complete growth medium. Two milliliters of 0.5% agar was cast into six-well plates and allowed to cool down for 15 min at 4 °C to form the bottom agar. Cells were trypsinized, and between 10,000 and 50,000 cells were diluted in 1 mL of complete growth medium. Subsequently, cells were mixed at a ratio of 1:1 with 1 mL of 0.8% agar and carefully layered onto the bottom agar. The six-well plates were left at room temperature for the agar to solidify before incubation in a standard tissue culture incubator. After 24 h, 1 mL of complete medium was carefully added on top of the agar to prevent cells from drying out. After 2 weeks, pictures were taken and colony size was measured using IMAGEJ (https://imagej.net/).

2.6. Quantitative real-time reverse transcriptase polymerase chain reaction

Reverse transcriptase polymerase chain reaction (RT-PCR) for gene expression analysis was performed with the ABI PRISM 7500 Sequence Detection System (Life Technologies, Darmstadt, Germany) as previously described (Ritschl et al., 2016). The primers for p66Shc were purchased as TaqMan Gene Expression Assay (Mm00465940m1; Applied Biosystems, Thermo Fisher Scientific, Foster City, CA, USA).

3. Results

3.1. Impaired p66ShcS36 phosphorylation and ROS levels in BRAFV600E-transformed cells

In a first set of experiments, we tested whether oncogenic BRAFV600E affects the expression or phosphorylation of p66Shc. Immortalized NIH 3T3 fibroblast cells, both parental (NIH 3T3 wt) and those expressing mutant BRAFV600E (NIH 3T3 V600E), were analyzed. While such a cellular model hardly reflects the complexity of cancer cells, it is well suited to study the effects of a single oncogenic mutation on individual aspects of the transformation process. Overexpression of oxidoreductase p66Shc in cancer has been frequently observed (Rajendran et al., 2010) and may serve to meet the increased need for higher ROS levels for proliferation and survival signaling. These experiments demonstrated that p66Shc protein expression was increased by approximately 2.5-fold in BRAFV600E-transformed cells (Fig. 1A, C), while the expression of the smaller isoforms p52Shc and p46Shc remained unaltered (Fig. S1). A similar increase was also observed for p66Shc mRNA expression (Fig. 1B).

Phosphorylation of p66Shc on serine 36 (S36) is essential for its pro-oxidant and pro-apoptotic function (Berniakovich et al., 2008; Galimov, 2010; Giorgio et al., 2005; Migliaccio et al., 1999; Nemoto and Finkel, 2002). Frequently applied chemotherapeutics act via increasing cellular ROS levels, including PEITC used here (Gupta et al., 2014; Jutooru et al., 2014). Basal p66ShcS36 phosphorylation was lower in BRAFV600E-transformed cells compared to wt cells (Fig. 1A, D). Moreover, while wt cells responded to PEITC treatment with a pronounced increase in S36 phosphorylation, this effect was negligible in BRAF-transformed cells (Fig. 1A, D). PEITC had no effect on p66Shc expression levels (Fig. 1A, D).

Signaling by oncogenic and wt CRAF and BRAF has been shown in the past to prevent stress-induced increase in mitochondrial ROS levels (Kuznetsov et al., 2008). Therefore, the effect of oncogenic BRAF on PEITC-induced ROS levels and cell death was studied. A concentration of 5 μM PEITC was sufficient to elicit a significant increase in ROS levels as recorded by confocal imaging following staining with Mitotracker Red CM-H2XRos (Fig. 2A) or FACS analysis of DCFDA-stained cells (Fig. 2B) in wt fibroblasts. In contrast, in BRAFV600E-transformed cells, the increase in ROS production in response to PEITC was significantly lower as compared to their wt counterpart (Fig. 2A, B). We next tested the effect of BRAFV600E mutation on cell survival following PEITC treatment. As described earlier for solid tumor cell lines (Trachootham et al., 2006), this fibroblast model of BRAFV600E transformation also showed significantly higher cell death rates than for their normal counterparts (Fig. 2C). Cell death induction by PEITC was prevented in cells pretreated with the antioxidant N-acetyl cysteine, confirming the causative role of ROS (Fig. S2).

3.2. MAPK signaling in BRAFV600E-transformed cells

Mitogen-activated protein kinase (MAPK) signaling is triggered by ROS, but also acts to control ROS levels. A limiting effect on ROS production has been described for signaling through RAF/MEK (Hermann et al., 2008; Kuznetsov et al., 2008), while activation of the stress kinases p38 and JNK1/2 resulted in increased mitochondrial ROS production (Ashraf et al., 2014; Haller et al., 2016; Khalid et al., 2016). RAF signaling is directly linked to the phosphorylation activation of MEK1/2 and its substrate ERK1/2 (Zebisch et al., 2007). Basal ERK1/2 phosphorylation was elevated in BRAFV600E-transformed cells, but...
both wt and transformed cell lines responded to PEITC treatment with strongly increased ERK1/2 phosphorylation (Fig. 3A, B). Also p38 activity rose following PEITC treatment of wt and BRAF-transformed cells to a similar extent (Fig. 3A, C). For JNK1/2, wt cells responded to PEITC treatment with increased JNK1/2 phosphorylation, which was not observed in BRAF-transformed cells (Fig. 3A, D).
Thus, JNK1/2 activation is selectively impaired in BRAF-transformed cells. To check whether this was restricted to the particular stimulus used here, we also tested sorbitol to activate JNK1/2 and observed the same suppressive effect of BRAFV600E on JNK1/2 activation (Fig. S3).

3.3. Effect of MAPK inhibitors on p66ShcS36 phosphorylation and ROS production in wt and NIH 3T3 BRAFV600E-transformed cells

We next analyzed the effect of inhibitors of MEK1/2 (AZD6244, AZD), BRAFV600E (PLX4032, PLX), and JNK1/2 (SP600125, SP) on p66ShcS36 phosphorylation following PEITC treatment. Among the inhibitors tested, PEITC-induced S36 phosphorylation in wt cells was partially inhibited by AZD and PLX and almost completely blocked by SP (Fig. 4A). As seen above (Fig. 1B), S36 phosphorylation was lower in transformed cells and unaffected by the inhibitors of MEK1/2 and oncogenic BRAF, while the inhibition of JNK1/2 completely prevented S36 phosphorylation (Fig. 4B). When analyzing JNK1/2 activation in the same samples, no significant effect was observed in the case of BRAF/MEK inhibitors, while SP demonstrated pronounced inhibition (Fig. 4B). This suggests that JNK1/2 activation does not depend on BRAF/MEK signaling. AZD had the expected effect on ERK1/2 phosphorylation, while PLX increased ERK1/2 phosphorylation in wt cells in agreement with published data (Hatzivassiliou et al., 2010), whereas decreased ERK phosphorylation was observed in NIH 3T3 BRAFV600E cells (Fig. 4C). Elevated ROS levels were observed in NIH 3T3 BRAFV600E cells following the inhibition of BRAF or MEK (Fig. 4D), while the inhibition of JNK1/2 prevented ROS production (Fig. 4D).

To further confirm that p66Shc really is a major contributor to ROS production in the cell model studied, stable shRNA-mediated knockdown of p66Shc was performed in wt and BRAFV600E-transformed fibroblasts and confirmed by immunoblotting (Fig. 5A, B). At the p66Shc protein level, a reduction by 50% was achieved in wt and transformed cells. This knockdown completely blocked PEITC-induced ROS production in wt cells (Fig. 5C). BRAFV600E-
transformed cells again demonstrated significantly lower ROS levels following PEITC treatment, which were not further affected by p66Shc knockdown.

3.4. Regulation of ROS levels in BRAFV600E-mutant melanoma cells

To further study signaling interactions, we switched to A375 cells, a melanoma cell line carrying the BRAFV600E mutation. A375 cells responded to PEITC treatment with ERK1 phosphorylation but also with the activation of JNK1 (Fig. 6A, B). Inhibiting BRAFV600E, MEK1/2, or JNK reduced S36 phosphorylation (Fig. 6C), while only SP was efficient in inhibiting ROS production. Again, BRAF and MEK inhibition resulted in increased ROS levels (Fig. 6D).

In a next set of experiments, we analyzed MAPK signaling, p66Shc activation, and ROS production in a pair of cell lines which either respond to vemurafenib treatment (M238) or have become resistant to it (M238R) (Nazarian et al., 2010). PEITC-induced increase in phospho-p66ShcS36 in parental cells was comparable to what had been observed in BRAF-transformed fibroblasts (Fig. 7A). Basal S36 phosphorylation was about fourfold higher in M238R cells and only marginally increased after PEITC treatment (Fig. 7A). Application of all inhibitors tested in this study reduced S36 phosphorylation (Fig. 7A), and JNK1 activity was equal in both cell lines and only responded to JNK inhibition (Fig. 7B). Finally, when comparing ROS production, our data showed that vemurafenib-resistant cells failed to respond to PEITC treatment with a pronounced increase in ROS, not even after BRAF/MEK inhibition (Fig. 7C). Thus, despite JNK activation and S36 phosphorylation, vemurafenib-resistant melanoma cells failed to respond with ROS production.

Fig. 4. Effect of MAPK inhibition on p66Shc activation and ROS production. A total of 500 000 cells were seeded in six-well plates in complete growth medium and treated with 20 μM of AZD6244, PLX4032, or SP600125, 1 h prior to PEITC treatment (30 min, 20 μM) prior to lysis. Immunoblots were carried out for the proteins indicated, and phosphorylation of p66Shc (A), JNK1 (B), or ERK1 (C) was quantified densitometrically. Data are presented as mean value ± standard error of the mean (SEM) of nine independent experiments. (D) ROS production was quantified as described in Fig. 2D. Data are presented as mean value ± standard error of the mean (SEM) of 100 measurements per sample and three experiments. *P < 0.1, **P < 0.01, ***P < 0.001.
3.5. Effect of p66Shc knockdown on BRAFV600E transformation

The data presented so far suggest that expression of oncogenic BRAFV600E blunts ROS production by preventing the activation of p66Shc. To further study the contribution of p66Shc to transformation, we performed a stable shRNA-mediated knockdown in BRAFV600E-transformed NIH 3T3 and A375 cells and tested the effect on growth in soft agar. As shown in Fig. 8A, B, the knockdown of p66Shc greatly enhanced proliferation of transformed cells, further supporting a tumor-suppressive effect of p66Shc. Representative pictures are shown in Fig. 8C.

4. Discussion

Metabolic rewiring to meet the increased need for biosynthesis is a common feature of transformed cells, which also opens up novel possibilities for therapeutic intervention. Most commonly, these changes affect key metabolic pathways, but also the increased production of ROS may be a direct result of these adaptations (Berger et al., 2017; Galluzzi et al., 2013; Kroemer and Pouyssegur, 2008; Ratnikov et al., 2017). The whole process is driven by oncogenic signaling pathways long implicated in the transformation process, but also metabolic enzymes are possible targets for mutation. Signaling through the small GTPase RAS and upstream oncogenes has been linked to the activation of NOX and thus increased ROS production (Bokoch and Knaus, 2003; Kamata, 2009). Other contributors may be the mitochondria themselves where mutations result in mitochondrial dysfunction causing increased ROS production (Yang et al., 2016b). Targeting ROS for therapeutic intervention is faced with the danger of tilting the balance to insufficient or excessive ROS levels also in nontransformed cells, which are both incompatible with cell survival. Knockout studies of NOX and inhibition of ROS production by the ETC of the mitochondria have highlighted the imminent danger of these approaches (Brand et al., 2016; Matsushima et al., 2013). In the case of p66Shc, the benefit of eliminating p66Shc function for the prevention of
oxidative stress-induced organ damage has been demonstrated for many disease settings, while no negative effects on normal physiological processes were noted (Giorgio et al., 2005). Also, no compensation by other ROS-producing systems was observed under these conditions. Inhibiting p66Shc function thus may be the preferred strategy for the prevention of pathologies associated with excessive ROS production, while activating p66Shc may be an approach to raise ROS levels in tumors in order to cause cell death.

We have shown previously that signaling through wt and activated CRAF and BRAF prevented excessive mitochondrial ROS levels (Kuznetsov et al., 2008). Inhibition of mutant BRAF in melanoma caused an increase in ROS production, which facilitated cell killing (Bauer et al., 2017; Verhaegen et al., 2006). In the work presented here, we provide evidence for a link between the presence of BRAF mutation and the inability of these cells to activate p66Shc. As we observe the same effect in BRAFV600E-transformed fibroblasts and melanoma cells carrying the same mutation, oncogenic BRAF on its own is sufficient to prevent p66Shc activation. With regard to the underlying mechanisms, our results point to a specific defect in the activation of JNK1/2 kinases, which are essential for phosphorylation activation of p66Shc. The reasons for this are still currently unknown. Cross talk between MAPKs signaling pathways has been reported and may involve phosphorylation and dephosphorylation events at different levels of the signaling cascades resulting in various outcomes with regard to activation of suppression of signal flow (Junttila et al., 2008; Kang et al., 2017; Lopez-Bergami et al., 2007; Meng and Xia, 2011; Shen et al., 2003). In our experiments, we observe ROS-dependent killing of BRAFV600E-
transformed cells despite their impaired ability for ROS production following PEITC stimulation. The increased sensitivity of transformed cells (in this case by the RAF upstream oncogenes KRASV12 and BCR-ABL) to treatments further increasing ROS levels has been reported before (Trachootham et al., 2006). RAF-transformed cells were not addressed in this study, but we have previously reported that onco-
genic RAF kinases will rather prevent excessive ROS production (Kuznetsov et al., 2008), as we observe here. Our data thus would suggest that the limited increase in ROS levels, which is observed in trans-
formed cells, is sufficient for cell death induction. The underlying mechanisms remain to be addressed in future experiments.

The inability to activate JNK1/2 in BRAFV600E-transformed cells is not limited to the specific stimu-
lus tested here, but was also seen when sorbitol was used to activate JNK1/2. In A375 cells, we observed that inhibition of BRAF/MEK also prevented S36 phosphorylation. Phosphorylation of S36 by ERK1/2, downstream of BRAF/MEK, appears possible, as this site conforms to a consensus site for phosphory-
lation by proline-directed kinases (Fujii et al., 2004) and ERK phosphorylation of S36 has been reported, for example, in glomerular mesangial cells after endothelin-1 stimulation (Foschi et al., 2001). We currently do not know why only JNK1/2 but not BRAF/MEK inhibition prevented ROS production. It appears possible that the increase in ROS levels as a consequence of BRAF/MEK inhibition, through p66Shc-independent mechanisms, surpasses the effect of p66Shc inhibition on overall ROS levels. The situation may be even more complex in cells which have become resistant to vemurafenib treatment. They show elevated p66Shc S36 phosphorylation but still fail to produce ROS. One possible explanation may be our previous demonstration that S36

Fig. 7. p66Shc and MAPK activity in M238/M238R after combined PEITC and inhibitor treatment. Cells were seeded in six-well plates at a density of 500 000 cells per well and treated with 20 μM of AZD6244, PLX4032, or SP600125, 1 hour prior to treatment with 20 μM PEITC for 30 min. Immunoblots were performed using phosphorylation-specific and total protein antibodies for p66Shc (A) and JNK1 (B). (C) For ROS measurements, cells were seeded in 8-well chamber slides and treated as described above before staining with 100 μM MitoTracker Red CM-H2XRos for 10 min. Data are presented as mean value ± standard error of the mean (SEM) of 100 measurements per sample and three experiments. *P < 0.1, **P < 0.01.
phosphorylation by JNK1/2 is insufficient for full p66Shc activation but requires additional phosphorylation by PKCβ (Haller et al., 2016).

The notion that the inability to activate p66Shc has tumor-suppressive function in melanoma cells is further supported by the results of the p66Shc knockdown in melanoma cells, which resulted in enhanced growth of melanoma cells in soft agar. This also suggests that restoring p66Shc activation may hold the key to a more efficient melanoma therapy. Understanding the mechanisms of p66Shc activation by upstream kinases JNK1/2 and PKCβ (Haller et al., 2016; Khalid et al., 2016), as we have recently investigated, holds the key for inhibition of p66Shc activation as it may be warranted in pathological settings characterized by excessive ROS production. Increasing ROS in cancer to induce cell death by selectively activating specific signaling pathways with cell-penetrating compounds is technically not feasible and most likely also would not overcome the block in JNK1/2 activation observed in our cellular models. A more feasible approach has been recently suggested by the demonstration that the breast cancer cell line MCF-7 can be killed by infection with viral p66Shc expression vectors. To circumvent the problem in p66Shc activation due to lacking JNK1/2 activity, a mutant form of p66Shc carrying glutamic acid (E) instead of serine (S) in position 36 could be used. This mutant has been shown to restore ROS production to mouse embryonic fibroblasts deficient in JNK1/2 (Khalid et al., 2016). That melanoma cells in general may be protected against an increase in p66Shc-dependent ROS production is also supported by the demonstration that the protein melanoma inhibitory activity (MIA) antagonizes p66Shc in melanoma (Kasuno et al., 2007). Inhibition of MIA by a synthetic peptide both decreased the number of metastases and led to immunosuppression in a murine model of malignant melanoma (Riechers and Bosserhoff, 2014).

5. Conclusion

Taken together, these data suggest that melanoma may be intrinsically deficient in mitochondrial ROS production by p66Shc. Overcoming this resistance may hold the key to novel therapies for the treatment of this cancer entity and may also be feasible in tumors resistant to currently used mutant BRAF inhibitors.

Acknowledgement

TF has been supported by a grant from the Austrian Cancer Society/Krebshilfe Tirol.
Author contributions

JT designed the study and drafted the final manuscript; TF, SK, and JT planned the experiments; TF, SK, AN, and JG performed the experiments, compiled, and analyzed the data; TF prepared the final figures. All authors read and approved the final manuscript.

References

Acin-Perez R, Salazar E, Kamenetsky M, Buck J, Levin LR and Manfredi G (2009) Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. Cell Metab 9, 265–276.

Ashraf MI, Ebner M, Wallner C, Haller M, Khalid S, Schwellberger H, Koziel K, Enthammer M, Hermann M, Sickinger S et al. (2014) A p38MAPK/MK2 signaling pathway leading to redox stress, cell death and ischemia/reperfusion injury. Cell Commun Signal 12, 6.

Bauer D, Werth F, Nguyen HA, Kiecker F and Eberle J (2017) Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells. Cell Death Dis 8, e2594.

Bensaad K and Vousden KH (2007) p53: new roles in cell survival and metabolism. Trends Cell Biol 17, 286–291.

Berger T, Saunders ME, Mak TW (2017) Beyond the oncogene revolution: four new ways to combat cancer. Cell Metab 25, 582–592.

Berniaikovich I, Trinei M, Stendardo M, Migliaccio E, Minucci S, Bernardi P, Pelicci PG and Giorgio M (2008) p66Shc-generated oxidative signal promotes fat accumulation. J Biol Chem 283, 34283–34293.

Birben E, Sahiner UM, Sackesen C, Erzurum S and Kalayci O (2012) Oxidative stress and antioxidant defense. World Allergy Organ J 5, 9.

Bokoch GM and Knaus UG (2003) NADPH oxidases: not just for leukocytes anymore!. Trends Biochem Sci 28, 502–508.

Brand MD, Goncalves RL, Orr AL, Vargas L, Gerencser AA, Borch Jensen M, Wang YT, Melov S, Turk CN, Matzen JT et al. (2016) Suppressors of superoxide/H2O2 production at site IQ of mitochondrial complex I protect against stem cell hyperplasia and ischemia-reperfusion injury. Cell Metab 24, 582–592.

Churchill EN and Mochly-Rosen D (2007) The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Biochem Soc Trans 35, 1040–1042.

Foschi M, Franchi F, Han J, La Villa G and Sorokin A (2001) Endothelin-1 induces serine phosphorylation of the adaptor protein p66Shc and its association with 14-3-3 protein in glomerular mesangial cells. J Biol Chem 276, 26640–26647.

Fujii K, Zhu G, Liu Y, Hallam J, Chen L, Herrero J and Shaw S (2004) Kinase peptide specificity: improved determination and relevance to protein phosphorylation. Proc Natl Acad Sci U S A 101, 13744–13749.

Galadari S, Rahman A, Pallichankandy S and Thayyullathil F (2017) Reactive oxygen species and cancer paradox: to promote or to suppress? Free Radic Biol Med 104, 144–164.

Galimov ER (2010) The role of p66shc in oxidative stress and apoptosis. Acta Naturae 2, 44–51.

Galluzzi L, Kepp O, Vander Heiden MG and Kroemer G (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12, 829–846.

Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Peliccia G, Luzi L, Minucci S, Marcaccio M et al. (2005) Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122, 221–233.

Gorrini C, Harris IS and Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12, 931–947.

Gottlieb E and Tomlinson IP (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5, 857–866.

Gupta P, Wright SE, Kim SH and Srivastava SK (2014) Phenethyl isothiocyanate: a comprehensive review of anti-cancer mechanisms. Biochim Biophys Acta 1846, 405–424.

Haller M, Khalid S, Kremsler L, Fresser F, Furlan T, Hermann M, Guenther J, Drasche A, Leitges M, Giorgio M et al. (2016) Novel insights into the PKCbeta-dependent regulation of the oxidoreductase p66Shc. J Biol Chem 291, 23557–23568.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloo SL, Vigers G et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435.

Hermann M, Kuznetsov A, Maglione M, Smigelskaite J, Margreiter R and Troppmair J (2008) Reactive oxygen species-inducing anticancer agents. World Allergy Organ J 1, 4.

Junttila MR, Li SP and Westermark J (2008) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22, 954–965.

Jutooru I, Guthrie AS, Chadalapaka G, Pathi S, Kim K, Burghardt R, Jin UH and Safe S (2014) Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents. Mol Cell Biol 34, 2382–2395.
Kamata T (2009) Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100, 1382–1388.

Kang BS, Hwang YJ and Dong Z (2017) ERK1 directly interacts with JNK1 leading to regulation of JNK1/c-Jun activity and cell transformation. J Cell Biochem 118, 2357–2370.

Kasuno K, Naqvi A, Dericco J, Yamamori T, Santanham L, Mattagajasingh I, Yang S, Meyskens F, Bosserhoff A and Irani K (2007) Antagonism of p66shc by melanoma inhibitory activity. Cell Death Differ 14, 1414–1421.

Khalid S, Drasche A, Thurner M, Hermann M, Ashraf MI, Fresser F, Baier G, Kremsr L, Lindner H and Troppmair J (2016) c-Jun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66shc activation. Sci Rep 6, 20930.

Kim J, Kim J and Bae JS (2016) ROS homeostasis and metabolism: a critical liaison for cancer therapy. Exp Mol Med 48, e269.

King A, Selak MA and Gottlieb E (2006) Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25, 4675–4682.

Koziel K, Smigelskaite J, Drasche A, Enthammer M, Khalid S and Troppmair J (2013) RAF and antioxidants prevent cell death induction after growth factor abrogation through regulation of Bcl-2 proteins. Exp Cell Res 319, 2728–2738.

Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13, 472–482.

Kuznetsov AV, Smigelskaite J, Doblander C, Janakiraman M, Hermann M, Wurm M, Scheidl SF, Sucher R, Deutschmann A and Troppmair J (2008) Survival signaling by C-RAF: mitochondrial reactive oxygen species and Ca2+ are critical targets. Mol Cell Biol 28, 2304–2313.

Lebiedzinska-Arciszewska M, Opara M, Vega-Naredo I, Karkucinska-Wieckowska A, Pinton P, Duszyński J and Wieckowski MR (2015) The interplay between p66Shc, reactive oxygen species and cancer cell metabolism. Eur J Clin Invest 45(Suppl 1), 25–31.

Liu B, Chen Y and St Clair DK (2008) ROS and p53: a versatile partnership. Free Radic Biol Med 44, 1529–1535.

Liu Y, Li Q, Zhou L, Xie N, Nice EC, Zhang H, Huang C and Lei Y (2016) Cancer drug resistance: redox resetting renders a way. Oncotarget 7, 42740–42761.

Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S et al. (2007) Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11, 447–460.

Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14, 463–482.

Martindale JL and Holbrook NJ (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192, 1–15.

Matsushima S, Kuroda J, Ago T, Zhai P, Ikeda Y, Oka S, Fong GH, Tian R and Sadoshima J (2013) Broad suppression of NADPH oxidase activity exacerbates ischemia/reperfusion injury through inadvertent downregulation of hypoxia-inducible factor-lalpha and upregulation of peroxisome proliferator-activated receptor-alpha. Circ Res 112, 1135–1149.

Meng Q and Xia Y (2011) e-Jun, at the crossroad of the signaling network. Protein Cell 2, 889–898.

Migliaccio E, Giorgio M, Mele S, Pellici G, Reboldi P, Pandolfi PP, Lanfrancone L and Pelicci PG (1999) The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402, 309–313.

Naharian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Saegar H et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977.

Nemoto S and Finkel T (2002) Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295, 2450–2452.

Piccoli C, Scacco S, Bellomo F, Signorile A, Iuso A, Boffoli D, Scrima R, Capitanio N and Papa S (2006) cAMP controls oxygen metabolism in mammalian cells. FEBS Lett 580, 4539–4543.

Rajendran M, Thomps P, Zhang L, Veeramani S and Lin MF (2010) p66shc – a longevity redox protein in human prostate cancer progression and metastasis: p66shc in cancer progression and metastasis. Cancer Metastasis Rev 29, 207–222.

Ramanathan A and Schreiber SL (2009) Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci USA 106, 22229–22232.

Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB (2003) Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23, 7315–7328.

Ratnikov BI, Scott DA, Osterman AL, Smith JW and Ronai ZA (2017) Metabolic rewiring in melanoma. Oncogene 36, 147–157.

Riechers A and Bosserhoff AK (2014) Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large. Exp Dermatol 23, 12–14.

Rietschel PV, Ashraf MI, Oberhuber R, Mellitzer V, Fabritius C, Resch T, Ebner S, Sauter M, Klingel K, Pratschke J et al. (2016) Donor brain death leads to differential immune activation in solid organs but does not accelerate ischaemia-reperfusion injury. J Pathol 239, 84–96.
Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ, Rana A and Tzivion G (2003) Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. *J Biol Chem* **278**, 26715–26721.

Son Y, Kim S, Chung H-T, Pae H-O 2013. Chapter Two - Reactive oxygen species in the activation of MAP kinases. In Methods in Enzymology (Enrique C, Lester P, eds), pp. 27–48. Academic Press, Cambridge, MA.

Sucher R, Gehwolf P, Kaier T, Hermann M, Maglione M, Oberhuber R, Ratschiller T, Kuznetsov AV, Bosch F, Kozlov AV et al. (2009) Intracellular signaling pathways control mitochondrial events associated with the development of ischemia/reperfusion-associated damage. *Transpl Int* **22**, 922–930.

Trachootham D, Alexandre J and Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat Rev Drug Discov* **8**, 579–591.

Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. *Cancer Cell* **10**, 241–252.

Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC, Nikolovska-Coleska Z, Bengtson A, Nair R, Elder JT et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. *Cancer Res* **66**, 11348–11359.

Ward PS and Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. *Cancer Cell* **21**, 297–308.

Wellbrock C, Karasarides M and Marais R (2004) The RAF proteins take centre stage. *Nat Rev Mol Cell Biol* **5**, 875–885.

Xiao D and Singh SV (2010) p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. *Cancer Res* **70**, 3150–3158.

Yang Y, Karakashanova S, Hartwig W, D’Haese JG, Philippov PP, Werner J and Bazhin AV (2016b) Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. *J Cell Physiol* **231**, 2570–2581.

Yang X, Xu R, Lin Y, Zhen Y, Wei J, Hu G and Sun H (2016a) Recombinant adenovirus of human p66Shc inhibits MCF-7 cell proliferation. *Sci Rep* **6**, 31534.

Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H and Troppmair J (2007) Signaling through RAS-RAF-MEK-ERK: from basics to bedside. *Curr Med Chem* **14**, 601–623.

Zhu Y and Prives C (2009) p53 and metabolism: the GAMT connection. *Mol Cell* **36**, 351–352.

### Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

**Fig. S1.** Expression of the p46 and p52 isoforms of Shc is not affected by BRAFV600E.

**Fig. S2.** N-acetyl cysteine (NAC) prevents PEITC-induced cell death.

**Fig. S3.** BRAFV600E-transformed cells are impaired in JNK1/2 activation following stimulation with sorbitol.